Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial CarcinomaAndrea B. Apolo, Jonathan E. Rosenberg, William Y. Kim et al.|New England Journal of Medicine|2024Cited by 145
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.Minas P. Economides, Scot A. Niglio, Matthew I. Milowsky et al.|Journal of Clinical Oncology|2023Cited by 8